NCT07112053 2026-03-09
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
Phase 2 Recruiting
Clinical Trials
8 trialsNCT04715958 2026-02-17
Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer
Thomas Jefferson University
Phase 2/3 Recruiting
NCT06999798 2026-02-12
An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial
Mayo Clinic
Phase 1 Recruiting
NCT04275661 2026-02-04
Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery
Assiut University
Phase 2 Completed
NCT06876714 2026-02-04
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT04799535 2026-02-03
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
Mayo Clinic
Recruiting
NCT05989828 2026-01-14
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
University of Southern California
Phase 1 Suspended
NCT05408260 2026-01-05
A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
Thomas Jefferson University
Phase NA Completed